Colorectal Cancer Stem Cell Biomarkers : Biological Traits and Prognostic Insights
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Due to self-renewal, differentiation, and limitless proliferation properties, Cancer Stem Cells (CSCs) increase the probability of tumor development. These cells are identified by using CSC markers, which are highly expressed proteins on the cell surface of CSCs. Recently, the therapeutic application of CSCs as novel biomarkers improved both the prognosis and diagnosis outcome of colorectal Cancer. In the present review, we focused on a specific panel of colorectal CSC markers, including LGR5, ALDH, CD166, CD133, and CD44, which offers a targeted and comprehensive analysis of their functions. The selection criteria for these markersCancer were based on their established significance in Colorectal Cancer (CRC) pathogenesis and clinical outcomes, providing novel insights into the CSC biology of CRC. Through this approach, we aim to elevate understanding and stimulate further research for developing effective diagnostic and therapeutic strategies in CRC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Current pharmaceutical design - (2024) vom: 15. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Soleimani, Atena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ALDH |
|---|
| Anmerkungen: |
Date Revised 16.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0113816128291321240329050945 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371130999 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371130999 | ||
| 003 | DE-627 | ||
| 005 | 20240416233732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240416s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0113816128291321240329050945 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM371130999 | ||
| 035 | |a (NLM)38623972 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Soleimani, Atena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Colorectal Cancer Stem Cell Biomarkers |b Biological Traits and Prognostic Insights |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Due to self-renewal, differentiation, and limitless proliferation properties, Cancer Stem Cells (CSCs) increase the probability of tumor development. These cells are identified by using CSC markers, which are highly expressed proteins on the cell surface of CSCs. Recently, the therapeutic application of CSCs as novel biomarkers improved both the prognosis and diagnosis outcome of colorectal Cancer. In the present review, we focused on a specific panel of colorectal CSC markers, including LGR5, ALDH, CD166, CD133, and CD44, which offers a targeted and comprehensive analysis of their functions. The selection criteria for these markersCancer were based on their established significance in Colorectal Cancer (CRC) pathogenesis and clinical outcomes, providing novel insights into the CSC biology of CRC. Through this approach, we aim to elevate understanding and stimulate further research for developing effective diagnostic and therapeutic strategies in CRC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ALDH | |
| 650 | 4 | |a CD133 | |
| 650 | 4 | |a CD166 | |
| 650 | 4 | |a CD44 | |
| 650 | 4 | |a Cancer stem cell | |
| 650 | 4 | |a Colon cancer. | |
| 650 | 4 | |a LGR5 | |
| 700 | 1 | |a Saeedi, Nikoo |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Asady, Abdulridha Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Nazari, Elnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Hanaie, Reyhane |e verfasserin |4 aut | |
| 700 | 1 | |a Khazaei, Majid |e verfasserin |4 aut | |
| 700 | 1 | |a Ghorbani, Elnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Akbarzade, Hamed |e verfasserin |4 aut | |
| 700 | 1 | |a Ryzhikov, Mikhail |e verfasserin |4 aut | |
| 700 | 1 | |a Avan, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Mehr, Seyed Mahdi Hasanian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d 1998 |g (2024) vom: 15. Apr. |w (DE-627)NLM095430172 |x 1873-4286 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0113816128291321240329050945 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 04 | ||